Bipolar disorder organizations
Pro Research Analysisby 
Searched over 200M research papers
Bipolar Disorder Organizations: Key Roles and Contributions
National Depressive and Manic-Depressive Association (National DMDA)
Advocacy and Support Services
The National Depressive and Manic-Depressive Association (National DMDA) is a leading patient-directed organization focused on bipolar disorder. As the largest of its kind in the nation, it represents millions of individuals affected by this condition. The organization plays a crucial role in providing scientifically accurate and unbiased information to the public, addressing the widespread need for knowledge about bipolar disorder .
Public Engagement and Information Dissemination
National DMDA's outreach efforts are significant, with nearly 5000 monthly calls to their information line and a quarter million hits on their website. These interactions primarily involve providing information, helping individuals find specialized doctors, and referring them to DMDA support groups . Despite these efforts, the organization continues to face challenges due to the stigma surrounding mood disorders, which are often misperceived as personality flaws rather than legitimate medical conditions .
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD)
Collaborative Guidelines for Bipolar Disorder Management
The Canadian Network for Mood and Anxiety Treatments (CANMAT), in collaboration with the International Society for Bipolar Disorders (ISBD), has developed comprehensive guidelines for managing bipolar disorder. These guidelines, updated in 2009, provide evidence-based recommendations for treating various phases of bipolar disorder, including acute mania, bipolar depression, and maintenance treatment .
Treatment Recommendations
For acute mania, first-line treatments include lithium, valproate, and several atypical antipsychotics. Tamoxifen is suggested as a third-line augmentation option, while the combination of olanzapine and carbamazepine is not recommended . In managing bipolar depression, first-line options include lithium, lamotrigine, quetiapine monotherapy, and combinations such as olanzapine plus SSRI, and lithium or divalproex plus SSRI/bupropion. New data also support adjunctive modafinil as a second-line option, though aripiprazole monotherapy is not recommended .
Maintenance and Bipolar II Disorder
For maintenance treatment, lithium, lamotrigine, valproate, and olanzapine remain first-line options. New evidence supports quetiapine monotherapy and adjunctive therapy, aripiprazole monotherapy for preventing manic events, and risperidone long-acting injection monotherapy and adjunctive therapy, as well as adjunctive ziprasidone for preventing mood events . The guidelines also provide an expanded focus on bipolar II disorder, highlighting its significant clinical impact .
Conclusion
Organizations like the National DMDA and collaborative efforts such as those by CANMAT and ISBD play pivotal roles in the management and support of individuals with bipolar disorder. Through advocacy, public engagement, and evidence-based guidelines, these organizations strive to improve the understanding, treatment, and perception of bipolar disorder, despite ongoing challenges related to stigma and misinformation.
Sources and full results
Most relevant research papers on this topic